Hepatitis D Therapeutics Market Size, Share, and Industry Analysis, By Drug Class (Entry Inhibitors, Pegylated interferon (PEG-IFN), and Others), By Route of Administration (Parenteral and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies), and Regional Forecast, 2026-2034

Last Updated: March 16, 2026 | Format: PDF | Report ID: FBI114768

Hepatitis D Therapeutics Market Overview

The global hepatitis D (HDV) therapeutics market is experiencing significant growth, driven by the increasing incidence of chronic HDV infections. A rise in awareness and educational programs about hepatitis D leads to early diagnosis and treatment of the disease. This results in increasing demand for hepatitis D medications, such as antiviral drugs and interferon treatments, in turn driving the market growth. Additionally, regulatory support and approvals for new products are expected to boost the market growth.

For instance, according to the data published by the European Medicines Agency, in October 2024, the Committee for Medicinal Products for Human Use (CHMP) provided a positive opinion. It recommended changes in terms of marketing authorisation of Hepcludex, for the treatment of hepatitis delta virus (HDV) infection.

Hepatitis D is a liver infection caused by the hepatitis D virus (HDV). It is unique as it only infects individuals already infected with the hepatitis B virus (HBV). HDV can lead to severe liver diseases, such as cirrhosis, liver failure, and hepatocellular carcinoma.

Hepatitis D Therapeutics Market Driver

Rise in Incidence of Hepatitis D Boosts Market Growth

The global hepatitis D therapeutics market expansion is expected to be driven by an increase in the incidence of hepatitis D infection. Individuals infected with HBV are at a higher risk of being infected with HDV, thus, an increase in awareness and improved diagnostic tools in regions with high rates of Hepatitis B (HBV) infection is increasing the incidence of hepatitis D infection. The growing number of individuals diagnosed with hepatitis D is increasing the need for effective treatments to manage the infection, which drives the market growth.

For instance, according to the data published by the World Health Organization, in April 2025, approximately 5% of individuals with chronic hepatitis B (HBV) are also infected with the hepatitis D virus (HDV) globally.

Estimated HDV Prevalence in General HBsAg-positive Populations, by WHO Region, 2020

According to the data published in the National Center for Biotechnology Information, in September 2020, the projected data shows that the African region (AFR) has a higher prevalence of hepatitis D infection, followed by the region of the Americas.

Hepatitis D Therapeutics Market Restraint

Potential Side Effects Associated with Current Therapies is Expected to Hinder Market Growth

The potential side effects associated with current hepatitis D therapies are expected to hinder the market growth. The limited efficacy and poor tolerability of hepatitis D therapeutics restrict its widespread use by lowering its adoption rate, which significantly hinders the overall hepatitis D therapeutics market growth.

For instance, according to the data published by the World Health Organization, in April 2025, for the chronic HDV, pegylated interferon α (PEG-IFNα) is one of the widely used treatment options. Still, its widespread use has been hampered by several side effects, such as flu-like symptoms, neuropsychiatric issues, hematologic abnormalities, and gastrointestinal problems. These side effects directly impact patient adherence and can lead to treatment discontinuation, which hampers the market growth.

Hepatitis D Therapeutics Market Opportunity

Development of New Therapies is Expected to Provide Opportunities in Future

The development of new and innovative therapies is expected to offer market growth opportunities in the future. The emerging treatments, such as entry inhibitors and immune modulators, are expected to improve the management of hepatitis D and witness a substantial growth in the coming years. Additionally, ongoing clinical trials for novel drug development for HDV is also expected to increase the market growth in the near future.

For instance, in March 2025, Bluejay Therapeutics announced that the first patient had received treatment in their global phase 3 clinical trial named AZURE-1. This trial is designed to assess the effectiveness and safety of brelovitug, an immunoglobulin G1 (IgG1) monoclonal antibody, as a monotherapy for individuals living with chronic hepatitis delta (CHD)

Key Insights

The report covers the following key insights:

Prevalence of Hepatitis D, By Key Countries/Regions, 2024
New Product Launches, By Key Players
Pipeline Analysis, By Key Players
Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

Segmentation

By Drug Class	By Route of Administration	By Distribution Channel	By Region
Entry Inhibitors pegylated interferon (PEG-IFN) Others	Parenteral Others	Hospital Pharmacies Specialty Pharmacies Others	North America (U.S. and Canada) Europe (U.K., Germany, France, Spain, Italy, Scandinavia, and Rest of Europe) Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific) Latin America (Brazil, Mexico, and Rest of Latin America) Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)

Analysis by Drug Class

By drug class, the market is divided into entry inhibitors, pegylated interferon (PEG-IFN), and others.

The entry inhibitors segment held a substantial share of the market. This is due to the bulevirtide is the first and only approved drug in Europe that aims to treat hepatitis D infection, which drives the segment growth. This drug has a unique mechanism of action and demonstrated efficacy in clinical trials, which significantly drives the segment growth during the forecast period. Additionally, bulevirtide has a few advantages, such as high antiviral efficacy, high tolerance, and cost-effectiveness, which support the segment growth.

For instance, in May 2025, Gilead Sciences Inc. announced the final result from the phase 3 clinical trial, which demonstrated the long-term benefits of bulevirtide for HDV.

Analysis by Route of Administration

By route of administration, the market is divided into parenteral and others.

The parenteral segment is expected to grow significantly during the forecast period. This is due to its efficacy in delivering antiviral medications directly into the bloodstream, leading to improved outcomes for patients. The parenteral administration allows direct and efficient delivery of antiviral drugs to the liver, where the hepatitis D virus (HDV) replicates. This direct approach bypasses the digestive system and allows for higher concentrations of the drug to reach the target site, which increases the segment growth.

For instance, bulevirtide, the only approved medication in Europe used to treat hepatitis D, is administered through the parenteral route.

Analysis by Distribution Channel

Based on the distribution channel, the market is classified into hospital pharmacies, retail pharmacies & drug stores, and online pharmacies.

The hospital pharmacies held a significant share of the hepatitis D therapeutics market in 2024. The hospitals are the primary centers for the diagnosis and treatment of hepatitis D, which drives the segment's growth. Additionally, hospital pharmacies provide immediate access to medications to ensure timely treatment for the chronic hepatitis D infection, which supports the segment growth during the forecast period.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization to gain extensive market insights.

North America accounted for a significant share of the global hepatitis D therapeutics market in 2024.

The market growth is primarily attributed to a rise in the incidence of hepatitis B, as hepatitis D (HDV) is a satellite virus that requires hepatitis B (HBV) to replicate, which puts a larger population at risk of HDV infection. Additionally, ongoing research activities and clinical trials for the development of effective therapeutics for hepatitis D by key operating players also support the market growth in this region.

For instance, in March 2025, Vir Biotechnology, Inc. enrolled the first patient in its phase 3 ECLIPSE registration program. This program aims to evaluate the efficacy and safety of tobevibart in combination with elebsiran for the treatment of people living with chronic hepatitis delta (CHD).

Europe has a considerable share of the hepatitis D therapeutics market. The growth of the region is attributed to the rise in incidence of hepatitis D in certain regions, such as Eastern Europe and the Mediterranean region. Additionally, bulevirtide (hepcludex), an entry inhibitor for the treatment of hepatitis D, is the first therapy to receive conditional marketing authorization in Europe, which drives the market growth in this region.

The Asia Pacific region is the fastest-growing region in the global hepatitis D therapeutics market, driven by the rising incidence and awareness of hepatitis D. Additionally, advancements in treatment options and government support, such as public health initiatives, also support the market growth in this region.

Key Players Covered

The global hepatitis D therapeutics market is consolidated with a few key players. The report includes the profiles of the following key players:

Eiger BioPharmaceuticals, Inc. (U.S.)
Bluejay Therapeutics (U.S.)
Vir Biotechnology, Inc. (U.S.)
Gilead Sciences, Inc. (U.S.)
Huahui Health Ltd. (China)

Key Industry Developments

In November 2024, Bluejay Therapeutics announced that its monoclonal antibody, BJT-778, demonstrated exceptional results in a Phase 2 clinical trial for chronic Hepatitis D (CHD).
In April 2023, Huahui Health Ltd. announced that China's drug authority had awarded breakthrough therapy designation to HH-003 for the treatment of chronic Hepatitis D infection.